AUPH · Aurinia Pharmaceuticals Inc.
$15.24
-0.09 (-0.59%)
At close · Jul 23
Market Cap
$1.96B
Shares
128.60M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Peter Greenleaf | CEO | $5,858,590 |
| Matthew Donley | COO | $2,237,088 |
| Stephen Robertson | Chief Legal Officer, Corporate Secretary and Chief Compliance Officer | $2,126,510 |
| Joseph Miller | CFO | $2,102,747 |
| Gregory Keenan | Chief Medical Officer | $1,774,241 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Peter Greenleaf | CEO | $6,417,897 |
| Max Donley | COO | $2,514,527 |
| Matthew Donley | COO | $2,514,527 |
| Joseph Miller | CFO | $2,297,805 |
| Joe Miller | CFO | $2,297,805 |
| Stephen Robertson | General Counsel | $2,216,429 |
| Greg Keenan | CMO | $1,327,097 |
| Gregory Keenan | Chief Medical Officer | $1,327,097 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Peter Greenleaf | CEO | $10,573,359 |
| Matthew Donley | COO | $4,558,086 |
| Max Donley | COO | $4,558,086 |
| Joe Miller | CFO | $3,976,937 |
| Joseph Miller | CFO | $3,976,937 |
| Stephen Robertson | General Counsel | $3,598,254 |
| Volker Knappertz | Executive Vice President, Research & Development | $3,436,474 |
| Gregory Keenan | Chief Medical Officer | $1,531,697 |
| Greg Keenan | CMO | $1,531,697 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Peter Greenleaf | CEO | $8,837,397 |
| Max Colao | Chief Commercial Officer | $3,603,002 |
| Max Donley | COO | $3,312,497 |
| Joe Miller | CFO | $3,292,594 |
| Stephen Robertson | General Counsel | $3,240,355 |
| Neil Solomons | Chief Medical Officer | $3,222,128 |
| Volker Knappertz | Executive Vice President, Research & Development | $2,983,686 |
| Scott Habig | Former Chief Commercial Officer | $2,785,746 |
| Greg Keenan | CMO | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Peter Greenleaf | CEO | $1,240,821 |
| Max Donley | Chief Operating Officer | $730,638 |
| Stephen Robertson | General Counsel | $722,690 |
| Neil Solomons | Chief Medical Officer | $717,324 |
| Joe Miller | CFO | $710,465 |
| Max Colao | Chief Commercial Officer | $710,157 |
| Volker Knappertz | Executive Vice President, Research & Development | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Peter Greenleaf | CEO | $10,679,282 |
| Max Colao | Chief Commercial Officer | $4,845,900 |
| Joe Miller | CFO | $3,715,212 |
| Stephen Robertson | General Counsel | $3,566,863 |
| Max Donley | Chief Operating Officer | $3,338,217 |
| Neil Solomons | Chief Medical Officer | $2,977,334 |
| Dennis Bourgeault | CFO | $703,715 |
| Volker Knappertz | Executive Vice President, Research & Development | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Peter Greenleaf | CEO | $5,236,630 |
| Max Donley | Chief Operating Officer | $945,903 |
| Dennis Bourgeault | CFO | $580,847 |
| Joe Miller | CFO | — |
| Max Colao | Chief Commercial Officer | — |
| Stephen Robertson | General Counsel | — |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Dennis Bourgeault | CFO | $680,621 |
| Joe Miller | CFO | — |
| Peter Greenleaf | CEO | — |
| Max Donley | Chief Operating Officer | — |
| Max Colao | Chief Commercial Officer | — |
| Stephen Robertson | General Counsel | — |
Key facts
CIK
1600620
CUSIP
05156V102
13F (30d)
41 filings
41 filers
Visit website
Investor relations